Ronald DePinho, M.D.
Ronald DePinho, M.D. is a co-founder and SAB chair of Nirogy. He has had a distinguished career in cancer research at Albert Einstein, Dana-Farber/Harvard, and MD Anderson Cancer Center where he is currently Professor of Cancer Biology. At Harvard, he was an American Cancer Society Professor and founded and directed the Belfer Institute for Applied Cancer Science to enhance science-driven drug discovery. As president of MD Anderson (2011-2017), he dramatically enhanced its research excellence and he conceived and launched the Cancer Moon Shots Program which inspired the national cancer moonshot and generated practice-changing advances in cancer. His research program has made fundamental contributions to our understanding and treatment of cancer, aging, and degenerative disorders. He is a member of the National Academy of Science and National Academy of Medicine and recipient of many awards including the Ellis Island Medal of Honor and knighthood from Portugal. Dr. DePinho has founded numerous biotech companies including Aveo, Tvardi, Asylia, Stellanova, and Karyopharm, and served as an advisor for biotech and large pharma including Epizyme, Agios, Abbott, and GSK. He holds an M.D. with distinction from Albert Einstein College of Medicine, B.S. Biological Sciences from Fordham University, and honorary degrees from Harvard and Hofstra University. (Disclosure: Nirogy service is not related to his role at MD Anderson)
Rosa F. Hwang, M.D.
Dr. Hwang co-founded Stellanova and brings her expertise in the fields of surgical oncology, breast and pancreatic cancer, and translational research on the tumor microenvironment. She is currently a tenured Professor and surgeon-scientist with a joint appointment in the Departments of Breast Surgical Oncology and Surgical Oncology at MD Anderson Cancer Center in Houston, TX. She is also the Associate Medical Director for Surgery at the Nellie B. Connally Breast Center at MD Anderson. Her lab is focused on the role of cancer-associated fibroblasts in tumorigenesis and resistance to therapy and first identified DKK3 as a promising therapeutic target in pancreatic cancer. The anti-DKK3 antibody clones were developed in Dr. Hwang’s lab and have been licensed to Stellanova for drug development targeting cancer and its surrounding microenvironment. She holds an M.D. from the University of Maryland, completed surgery residency at the University of Southern California (USC Keck School of Medicine), clinical fellowship in Surgical Oncology at MD Anderson and a postdoctoral research fellowship in Cancer Biology with Dr. Isaiah J. Fidler at MD Anderson.
Emmanuelle Schuler, Ph.D., MBA
Dr. Schuler is passionate about bettering the lives of patients by impacting healthcare delivery through therapeutic innovation. She has over 20 years of expertise in strategic alliances, joint ventures, and intellectual assets that have brought together entrepreneurs, inventors, and clinicians to reimagine medical breakthroughs. Prior to joining the founding team of Stellanova, Schuler has been a member of the founding team at several companies, including JLABS @ TMC, where she spearheaded successful site operations and business development, and Corallis Consulting which focused on improving therapeutic solutions in conjunction with publicly traded companies based in the United States and Europe. Dr. Schuler holds a B.Sc. in Chemistry from Université du Québec à Montréal, a Ph.D. in Chemistry from McGill University followed by a post-doc with Chemistry Nobel Laureate Rick Smalley, and an MBA in Business and Strategy from Rice University.
Jeno Gyuris, Ph.D.
President & Chief Scientific Officer
Jeno Gyuris, Ph.D. is an experienced biotech executive with over 25 years of scientific leadership experience in basic cancer research as well as oncology drug discovery and development. A veteran of the Cambridge biotech cluster, Jeno previously served as the Chief Scientific Officer of Trieza Therapeutics, Quiet Therapeutics and Aveo Pharmaceuticals. Jeno and his team discovered and contributed to the development of several drugs currently in clinical trials and one approved drug. He received his Ph.D. from the University of Szeged, Hungary, and completed postdoctoral training at Harvard Medical School and Massachusetts General Hospital.